Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | MMP1 | P03956 | 3/20 | 0.34 |
| ▸ | MMP2 | P08253 | 3/20 | 0.34 |
| ▸ | MMP3 | P08254 | 3/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.32 |
| ▸ | MMP9 | P14780 | 2/20 | 0.32 |
| ▸ | MMP8 | P22894 | 1/20 | 0.32 |
| ▸ | MMP13 | P45452 | 1/20 | 0.32 |
| ▸ | MMP14 | P50281 | 1/20 | 0.32 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.32 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL241919 | 0.83 | MMP2 (0.46) | MMP1MMP2MMP3MMP9MMP8 | |
| SCHEMBL2785652 | 0.81 | MCL1 (0.40) | ATMMMP2LMNAMCL1MMP9 | |
| SCHEMBL12057490 | 0.81 | MAPT (0.45) | MMP1MMP2MMP3PIK3CDMAPT | |
| SCHEMBL12072365 | 0.79 | MCL1 (0.36) | MMP1MMP2MMP3MCL1MMP9 | |
| SCHEMBL28343319 | 0.78 | CYP2D6 (0.43) | MMP1LMNAMMP8 | |
| SCHEMBL24433805 | 0.77 | ATM (0.34) | ATMLMNAMCL1 | |
| SCHEMBL26107407 | 0.77 | CA2 (0.35) | MMP1MMP2MMP3 | |
| SCHEMBL10420638 | 0.76 | SMN1; SMN2 (0.39) | MAPT | |
| SCHEMBL17584788 | 0.76 | CA2 (0.46) | MMP1MMP2MMP3 | |
| SCHEMBL13785286 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019136025-A1 | ASK1 INHIBITOR COMPOUNDS AND USES THEREOF | Seal Rock Therapeutics, Inc. (US) | 2019-07-11 | — | — | WO | disclosed |
| US-9068137-B2 | Water-mixed metal working fluids containing ether pyrrolidone carboxylic acids | CLARIANT FINANCE (BVI) LIMITED (VG) | 2015-06-30 | — | — | US | disclosed |
| US-8759264-B2 | Water-based hydraulic fluids comprising dithio-di(aryl carbolic acids) | CLARIENT FINANCE (BVI) LIMITED (VG) | 2014-06-24 | — | — | US | disclosed |
| US-20120088705-A1 | POLYALKYLENE GLYCOL-BASED ETHER PYRROLIDONE CARBOXYLIC ACIDS, AND CONCENTRATES FOR THE PRODUCTION OF SYNTHETIC COOLING LUBRICANTS CONTAINING THE SAME | CLARIANT FINANCE (BVI) LIMITED (VG) | 2012-04-12 | — | — | US | disclosed |
| EP-1966191-B1 | SUBSTITUTED PYRAZINONE DERIVATIVES AS ALPHA2C-ADRENORECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2010-03-17 | — | — | EP | disclosed |
| US-20080269251-A1 | Substituted Pyrazinone Derivatives as Alpha2C-Adrenoreceptor Antagonists | ANDRE-GIL JOSE IGNACIO | 2008-10-30 | — | — | US | disclosed |
| US-20080269251-A1 | Substituted Pyrazinone Derivatives as Alpha2C-Adrenoreceptor Antagonists | ANDRE-GIL JOSE IGNACIO | 2008-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088705-A1 | POLYALKYLENE GLYCOL-BASED ETHER PYRROLIDONE CARBOXYLIC ACIDS, AND CONCENTRATES FOR THE PRODUCTION OF SYNTHETIC COOLING LUBRICANTS CONTAINING THE SAME | F12, ADH1A, ADH1C | ATM 3054/4885MMP1 2680/4885MMP2 3513/4885 |
| US-20080269251-A1 | Substituted Pyrazinone Derivatives as Alpha2C-Adrenoreceptor Antagonists | ADRA2C, ADRB2, ADRA2A | ATM 1671/4885MMP1 4714/4885MMP2 4222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.